TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share purchase agreement. Juno GmbH was previously owned by Bristol Myers Squibb. Financial terms have not been disclosed.
The acquisition expands TQx’s access to intellectual property and licensing agreements that will support the development of its decentralised, automated cell and gene therapy (CGT) platform. The company is advancing a bedside-compatible system designed to reduce production times and improve scalability in extracorporeal cell therapy.
“This acquisition enables us to accelerate development of our ultra-short CGT platform,” said Christian Eckert, CEO of TQx. “It supports our goal of making advanced therapies more accessible and cost-effective.”
TQx is focused on transforming cell therapy manufacturing by moving away from centralised infrastructure toward on-site processing. Its platform is designed to deliver individualised therapies with reduced logistical and operational burden.
Juno GmbH previously operated as part of Bristol Myers Squibb’s European cell therapy portfolio. TQx has not disclosed operational integration plans following the acquisition.
The deal forms part of TQx’s strategy to advance technologies that broaden access to CGT treatments across a wider range of healthcare settings.
